CR845

Phase 3Small molecule

CCara Therapeutics, Inc.

CR845 is one of 122 small molecule programs targeting Hysterectomy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

121

Competitors

Pipeline

Status by Indication[3][1]

Indication

HysterectomyActive, not recruiting

Primary Biliary CholangitisActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

OsteoarthritisActive, not recruiting

HysterectomyPhase 2

Active, not recruiting

Primary Biliary CholangitisPhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 2

Active, not recruiting

OsteoarthritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

CR845

CCara Therapeutics, Inc.

Phase 3

2 2

Catapres

Boehringer Ingelheim

Preclinical

1 3

Paracetamol

GSK

Preclinical

4 4

Naproxen Sodium

Bayer

Preclinical

1 5

Ansaid

PPharmacia and Upjohn

Preclinical

—6

Decadron

QQuince Therapeutics S.p.A.

SGLT2 Inhibitor

1 8

Acetyl-L-Carnitine

Mario Negri Institute for Pharmacological Research

Preclinical

1 9

Lornoxicam

PPOZEN

Preclinical

1 10

Phenol

NNorthwestern University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pruritus5 trials

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Completed·CCara Therapeutics, Inc.·Phase 3·NCT03281538·288 enrolled

CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Completed·CCara Therapeutics, Inc.·Phase 3·NCT03636269·473 enrolled

Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Completed·CCara Therapeutics, Inc.·Phase 2/3·NCT02858726·226 enrolled

Show 2 more trials

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

Completed·CCara Therapeutics, Inc.·Phase 3·NCT03422653·378 enrolled

CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Completed·CCara Therapeutics, Inc.·Phase 3·NCT03998163·222 enrolled

Hysterectomy2 trials

Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery

Completed·CCara Therapeutics, Inc.·Phase 2·NCT01361568·203 enrolled

Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery

Completed·CCara Therapeutics, Inc.·Phase 2·NCT00877799·114 enrolled

Osteoarthritis2 trials

A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

Completed·CCara Therapeutics, Inc.·Phase 2·NCT02524197·81 enrolled

A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee

Completed·CCara Therapeutics, Inc.·Phase 2·NCT02944448·761 enrolled

Analgesic1 trial

A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery

Completed·CCara Therapeutics, Inc.·Phase 2·NCT01789476·51 enrolled

End-Stage Renal Disease1 trial

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

Completed·CCara Therapeutics, Inc.·Phase 1·NCT03947970·12 enrolled

5 more indications

Primary Biliary Cholangitis1 trial

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

Terminated·CCara Therapeutics, Inc.·Phase 2·NCT03995212·14 enrolled

Chronic Kidney Disease1 trial

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Completed·CCara Therapeutics, Inc.·Phase 2·NCT03617536·269 enrolled

Dialysis Patients1 trial

CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients

Completed·CCara Therapeutics, Inc.·Phase 1·NCT05533008·35 enrolled

Abdominal Surgery1 trial

A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery

Completed·CCara Therapeutics, Inc.·Phase 2/3·NCT02542384·451 enrolled

Intravenous1 trial

Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects

Completed·CCara Therapeutics, Inc.·Phase 1·NCT04019574·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for CR845. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CR845 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CR845. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cara Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCara Therapeutics, Inc.

CR845

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pruritus5 trials

Hysterectomy2 trials

Osteoarthritis2 trials

Analgesic1 trial

End-Stage Renal Disease1 trial

Primary Biliary Cholangitis1 trial

Chronic Kidney Disease1 trial

Dialysis Patients1 trial

Abdominal Surgery1 trial

Intravenous1 trial

References

Drug Info

Quick Facts

Related News